FDA Approves First New Molecular Entity Under National Priority Voucher Program
The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth appro...
Publisher
USA
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Summary excerpt
The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth appro...
Source route
Continue on fda.gov
Leave the platform to read the original full article on the publisher site.
Source: FDA News
Scope: Regulatory
Related coverage
More related coverage
FDA warns patients and health care professionals not to use sterile products from North American Custom Laboratories LLC, dba FarmaKeio Superior Custom Compounding
FDA is warning patients and health care professionals not to use products intended to be sterile pro...
Aphreseller (Buy-herbal.com) Issues Voluntary Nationwide Recall of Kian Pee Wan Capsules Due the Presence of Undeclared Dexamethasone and Cyproheptadine
FOR IMMEDIATE RELEASE – 03/30/2026 - Flushing, New York, Aphreseller (Ebay seller ID), Buy-herbal.co...
Requesting an FDA Patient-Led Listening Session
Learn about how to request a Patient Listening Session with the FDA to share your experiences and pe...
Suggested Sample Agenda for an FDA Patient-Led Listening Session
View a suggested sample agenda an FDA Patient-Led Listening Session